What was the value per share used for the Emergent BioSolutions (EBS) tax withholding?

The filing indicates a value of $8.00 per share for the 2,018 Emergent BioSolutions shares withheld. This figure is used solely to calculate the tax payment related to the vesting and settlement of restricted stock units granted as part of compensation.

Emergent executive covers taxes with 2,018 EBS shares

Emergent BioSolutions Inc. executive Coleen Glessner reported a routine tax-related share disposition.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Emergent BioSolutions Inc. executive Coleen Glessner reported a routine tax-related share disposition. On the vesting and settlement of restricted stock units, 2,018 shares of common stock were withheld to cover associated taxes at an indicated value of $8.00 per share. After this withholding, she directly holds 202,201 shares of Emergent BioSolutions common stock, so the filing reflects a compensation and tax event rather than an open-market trade.

Insider Trade Summary

Exercise Price or Tax Liability: 2,018 shares

Exercise Price or Tax Liability 1 txn

Insider Glessner Coleen

Role EVP, Quality & Ethics, and CPL

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,018	$8.00	$16K

Holdings After Transaction: Common Stock — 202,201 shares (Direct)

Footnotes (1)

F1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

Key Figures

Shares withheld for taxes: 2,018 shares Per-share tax value: $8.00 per share Shares held after transaction: 202,201 shares

3 metrics

Shares withheld for taxes 2,018 shares Common stock withheld for RSU tax obligations

Per-share tax value $8.00 per share Value applied to withheld common stock

Shares held after transaction 202,201 shares Direct Emergent BioSolutions common stock holdings post-event

Key Terms

restricted stock units, tax-withholding disposition, Form 4

3 terms

restricted stock units financial

"vesting and settlement of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition" for common stock."

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): disclosure of the transaction."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Emergent BioSolutions (EBS) report for Coleen Glessner?

Emergent BioSolutions reported that executive Coleen Glessner had 2,018 shares of common stock withheld to cover taxes on vesting restricted stock units. This was a compensation-related tax event, not an open-market purchase or sale of EBS shares.

Was the Emergent BioSolutions (EBS) insider transaction a market sale of shares?

No, the transaction was not a market sale. The 2,018 EBS shares were withheld by the company to pay taxes when restricted stock units vested, a common non-market mechanism for satisfying tax obligations on equity compensation.

How many Emergent BioSolutions (EBS) shares does Coleen Glessner hold after this transaction?

Following the tax withholding, Coleen Glessner directly holds 202,201 shares of Emergent BioSolutions common stock. This remaining stake shows the disposition was small relative to her overall equity position and reflects a routine tax event tied to compensation.

What does the Form 4 tax-withholding disposition mean for Emergent BioSolutions (EBS) investors?

The Form 4 shows a routine tax-withholding disposition tied to equity compensation, not a discretionary trade in EBS shares. Such events typically have limited informational value about insider sentiment, as they occur automatically when restricted stock units vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/10/2026 - 03:07 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glessner Coleen

(Last)

(First)

(Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG

MARYLAND

20879

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Quality & Ethics, and CPL

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2026		F		2,018⁽¹⁾	D	$8	202,201	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR